Sources reviewed include: the official FeelGood website at feelgoodmeds.com, the brand's published Cancellation and Refund Policy, Terms of Use (last updated July 2025), the OpenLoop Healthcare Partners, PC telehealth consent form published at openloophealth.com, LegitScript verification data, and category-level published research on GLP-1 receptor agonists from NIDDK, NIH, and peer-reviewed clinical literature
Safarinejad MR, Safarinejad S
According to the results of both DAPA-HF [13] and EMPEROR-R [14], the FDA have approved both dapagliflozin and empagliflozin to reduce the risk of CV death or hospitalization for HF in adults with HF and reduced ejection fraction regardless of whether they have diabetes
It is a 39-amino-acid peptide on a glucagon-family backbone, with Aib substitutions and a C20 fatty diacid attached through a Glu-2xOEG linker
This degradation process leads to the release of encapsulated drugs